Abstract N-acetylcysteine (600 mg/day) was given to patients by mouth for five days before bronchoscopy and bronchoalveolar lavage to determine whether N-acetylcysteine could increase the concentrations of the antioxidant reduced glutathione in plasma and bronchoalveolar lavage fluid. Bronchoalveolar lavage was performed 1-3 hours (group 2, n = 9) and 16-20 hours (group 3, n = 10) after the last dose of N-acetylcysteine and the values were compared with those in a control group receiving no N-acetylcysteine (group 1, n = 8). N-acetylcysteine was not detected in plasma or lavage fluid. Plasma concentrations of cysteine, the main metabolite of Nacetylcysteine and a precursor of reduced glutathione, were greater in the groups receiving treatment (groups 2 and 3) than in group 1. Cysteine concentrations in lavage fluid were similar in the three groups. Concentrations of reduced glutathione were greater in both plasma and lavage fluid in group 2 than in group 1. These data suggest that Nacetylcysteine given by mouth is rapidly deacetylated to cysteine, with resulting increases in the concentrations of cysteine in plasma and of reduced glutathione in plasma and the airways, which thus temporarily increase the antioxidant capacity of the lung.
An imbalance may occur in the distal airspaces of the lung between oxidants and antioxidants and may have a role in the pathogenesis of emphysema.'2 Oxidants, produced by inflammatory cells during endogenous metabolism, xenobiotic insult, or both, may cause degradation of lung connective tissue' and inactivate antiproteases.34 Enhancement of the antioxidant capacity of both blood and the distal airspaces may therefore prevent oxidative damage to the lung, though the role of an oxidant-antioxidant imbalance in the pathogenesis of lung injury remains to be proved. 5 During the past 20 years the antioxidant Nacetylcysteine has been used to treat patients with chronic obstructive pulmonary disease. 6 Long term oral administration of N-acetylcysteine reduces the number of acute exacerbations in patients with chronic obstructive disease,78 though the mechanism underlying this effect remains unclear. N-acetylcysteine protects lung epithelial cells in vitro against oxidant injury mediated by polymorphonuclear leucocytes9 and dogs against pulmonary oxygen toxicity in vivo."0 Thus Nacetylcysteine has antioxidant potential and its main metabolite, cysteine, a precursor in the biosynthesis of reduced glutathione, is an extremely important intracellular and extracellular antioxidant.'1 12 The aim of this study was to determine if N-acetylcysteine given by mouth could increase the concentrations of the antioxidants cysteine and reduced gluytathione in plasma and in bronchoalveolar lavage fluid in man.
Methods
All patients were undergoing routine diagnostic bronchoscopy for the investigation of a lung tumour. Three groups ofpatients were studied. Group 1 (n = 10) acted as a control group and received no N-acetylcysteine. Groups 2 and 3 (both n = 12) received N-acetylcysteine in a single daily dose of 600 mg for five days. Bronchoalveolar lavage was performed either 1-3 hours (group 2) or 16-20 hours (group 3) after the last dose of N-acetylcysteine. The patients were randomly assigned to the groups. One patient in each group had chronic obstructive pulmonary disease and none had pulmonary fibrosis. Informed consent was given by all the patients and permission was obtained from our local ethics committee.
SAMPLES
Plasma and bronchoalveolar lavage samples were obtained from three groups of patients: group 1 (n = 8, six male; mean age 70 (range 35-77) years), consisting of three smokers, three ex-smokers, and two non-smokers; group 2 (n = 9, eight male; mean age 65 (range 48-73) years), consisting of six smokers, and three ex-smokers; group 3 (n = 10, eight male; mean age 59 (range 31-71) years), consisting of two smokers, six ex-smokers, and two nonsmokers.
Bronchoalveolar lavage fluid Fibreoptic bronchoscopy was performed under local anaesthesia (2% topical lignocaine) after premedication with diamorphine and atropine. The bronchoscope was wedged in a segmental bronchus in the lung contralateral to the tumour and 30 ml aliquots of warmed sterile saline (to a total volume of 240 ml) were instilled and recovered. The volumes instilled and returned were recorded. Lavage fluid was immediately filtered through four sterile gauze swabs and then centrifuged at 4°C for 10 minutes at 150 g to remove cells. The supernatant was removed and centrifuged again at 4°C for 10 minutes at 1400 g, to produce completely cell free fluid.
Blood samples Venous blood samples (5 ml) were drawn into lithium heparin at the time of bronchoalveolar lavage and centrifuged at 4°C for 10 minutes at 800 g to obtain plasma.
ASSAYS

Thiol determinations
Concentrations of cysteine, reduced glutathione and free N-acetylcysteine were measured.'3 Immediately after centrifugation the sample of plasma or lavage fluid (100 dl) was mixed with 8 mM monobromobimane (Thiolyte, Calbiochem) in 50 mM N-ethylmorpholine, pH 8-0 (100 pl), and phosphate buffered saline, pH 7-4 (10 p1). Monobromobimane is relatively insoluble in aqueous solutions and was predissolved in a small amount of acetonitrile. The sample was stored in the dark at room temperature for five minutes and then acidified to stop the reaction by the addition of 100% (w/v) trichloroacetic acid. The precipitated protein was removed by centrifugation for 10 minutes with a microfuge (Microcentaur, MSE) at high speed. Aliquots of the supernatants (100 pl) were applied to a high pressure liquid chromatography column.
Chromatography
The chromatographic separation of the thiolmonobromobimane derivatives was achieved using a Waters (Milford, Massachusetts) Nova-Pak steel column (3-9 x 150 mm) packed with 4 pm octadodecyl silica reversed phase material. The analytical column was protected by a small Waters Guard-Pak precolumn packed with the same material. The chromatographic system consisted of two Model 410 pumps, an automated gradient controller, a Waters intelligent sampler processor model 710 (automatic injection system), and a data module (M730) for peak integration. A fluorescence detector, model 420, was used for peak detection (all from Waters). The elution solvent A was 8-5% (v/v) acetonitrile, 0-25% (v/v) acetic acid, and 0-25% (v/v) perchloric acid, pH 3-65; and solvent B was 75% (v/v) acetonitrile in distilled water.
Isocractic conditions (100% A) were maintained for 14 minutes, then changed to 100% B for 10 minutes and thereafter immediately returned to 100% A for re-equilibration for six minutes. The flow rate was maintained at 1 ml/ min.
Standard solutions of cysteine, reduced glutathione, and N-acetylcysteine were prepared daily with phosphate buffered saline (pH 7 4) in the same way as the test solutions. The limit of the detection was 5 pmol on column. The coefficient of variation of the assay was 5% for repeated analyses of standard solutions (n = 20).
Other assays
Albumin and ac,-proteinase inhibitor concentrations were determined with an enzyme linked immunosorbent assay (ELISA) with unconjugated (Cappel Laboratories, Dynatech) and peroxidase conjugated (Dakopatts) antisera to human albumin and a,-proteinase inhibitor. 14 The coefficient of variation for both assays was 5%. Catalase activity was determined spectrophotometrically. 11 ' 
LAVAGE FLUID FINDINGS
Because of the uncertain, and probably variable, dilution of the epithelial lining fluid that occurs during bronchoalveolar lavage, concentrations of the thiols in lavage fluid were also expressed in relation to albumin concentrations. Cysteine:albumin ratios in bronchoalveolar lavage fluid did not differ significantly from those of the control group in either group 2 or group 3, though they tended to be higher in group 2 (fig 1) . Reduced glutathione concentrations in lavage fluid, when corrected for albumin, were higher in group 2 (lavage performed 1-3 hours after the last dose of N-acetylcysteine) than in the control group (p < 0-05) but not in group 3 (fig 2) . The increase in (ONAC) though this increase was short lived and was not present 20 hours after the last dose of Nacetylcysteine. The transience of the increase is :)n presumably due to its rapid removal from plasma by the kidney or by feedback inhibition of y-glutamylcysteine synthetase by glutathione,25 or to both mechanisms.
In lavage fluid the position was reversed; cysteine concentrations did not increase significantly after N-acetylcysteine administration, whereas reduced glutathione concentrations in lavage fluid were higher in those patients who had received N-acetylcysteine up to three hours before lavage. This increase was short lived and was not present 20 hours after p-----1 the last dose of N-acetylcysteine. As lactate 
